IntegraGen reports sales of €4.7 million in the first half of 2020, up 13%, and cash position of €5.8 million
09 Juillet 2020 - 7:45AM
Business Wire
- Continued sales growth linked to increase in sequencing
activities
- Moderate impact of the pandemic on sales of software tools
to aid in the interpretation of genomic data
- Successful implementation of measures to adapt to the health
crisis and preservation of cash resources
Regulatory News:
IntegraGen (FR0010908723 – ALINT – Eligible PEA PME)
(Paris:ALINT), a company specializing in the decryption of the
human genome which performs interpretable genomic analyzes for
academic and private laboratories and develops diagnostic tools for
oncology, today announced its unaudited sales for the first half of
2020.
Unaudited sales during the first half of 2020 were 4,706 k€, an
increase of 13% compared to the first half of 2019 and 15% on a
like-for-like basis taking into account the sale of the company’s
diagnostic business at the start of 2020. The growth in sales was a
result of an increase in all sequencing activities, in particular
the SeqOIA platform (+33%), activities related to outsourced
platforms (+18%), and sequencing services for research and clinical
research (+9%).
Software and genomic consulting (GeCo) activities were limited
due to the pandemic, which notably resulted in the delay of
projects.
The company’s cash position at the end of June 2020 was 5.8 m€,
representing an improvement of almost 3.0 m€ compared to the cash
position as of December 31, 2019. This difference is mainly due to
the receipt of a State Guaranteed Loan (PGE) totaling 1.8 m€, to
the implementation of several safeguarding actions during the
confinement period linked to the COVID-19 pandemic, and to an
equilibrium between the consumption of cash for current operations
and business revenue.
Bernard Courtieu, Chairman and Chief Executive Officer of
IntegraGen stated, “our sales revenue during the first half of 2020
builds on the previously reported profitable growth trajectory
which we experienced during the second half of 2019. These results
reinforce our current strategy of focusing on our genomic services
business with an emphasis on sequencing and data interpretation.
Despite the difficulties linked to the pandemic, sales of our
software tools to assist with genomic data interpretation remain a
major strategic focus, as evidenced by the announcement in April of
an agreement with a major cancer center in the United States. The
sustained growth and healthy cash position we have achieved despite
the current crisis will enable us to pursue a positive and
ambitious trajectory. Lastly, I would like to thank the employees
of IntegraGen who have demonstrated exemplary solidarity and
dedication to ensuring continuity of operations during containment
linked to the pandemic."
The financial results for the first half of 2020 will be
published on September 17, 2020.
About IntegraGen
IntegraGen is a company specializing in the analysis of the
human genome and performs adaptive and quickly interpretable
analyses for academic and private laboratories. For the management
of cancers, which are characterized by a genetic disruption of
cells, IntegraGen provides researchers and doctors with universal
and individualized therapeutic guidance tools allowing them to
adapt the treatment to the patient's genetic profile.
IntegraGen has forty-six employees and generated revenue of €
8.3 million in 2019. Based in the Génopole d'Evry, IntegraGen is
also located in the United States in Cambridge, MA. IntegraGen is
listed on Euronext Growth in Paris (ISIN: FR0010908723 - Mnemo:
ALINT - Eligible PEA-PME).
For more information, visit www.integragen.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200708005952/en/
IntegraGen Bernard COURTIEU President and CEO
Laurence RIOT LAMOTTE Chief Financial Officer
contact@integragen.com Tel: +33 (0)1 60 91 09 00
NewCap Investor and Media Relations Louis-Victor
DELOUVRIER integragen@newcap.eu Tel: +33 (0)1 44 71 98 53
Integragen (EU:ALINT)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Integragen (EU:ALINT)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024